# UNC Lineberger Comprehensive Cancer Center

Source: https://onco.cc/institutions/unc-lineberger/  
OnCo record `unc-lineberger` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Where Charles Perou defined the PAM50 intrinsic subtypes of breast cancer; a public university centre with in-house CAR-T manufacturing.

## Summary

NCI-designated since 1975 and comprehensive since 1990, UNC Lineberger is a public-university cancer centre with a statewide remit across North Carolina. Charles Perou's intrinsic subtypes and the PAM50 assay reshaped breast cancer classification; Norman Sharpless, later NCI director, worked on CDK4/6 and cellular senescence here and co-founded G1 Therapeutics. Gianpietro Dotti and Barbara Savoldo run one of the few academic in-house CAR-T programmes, and Ethan Basch's patient-reported outcome trials changed how symptoms are monitored during chemotherapy. Blossom Damania and Dirk Dittmer lead research on Kaposi sarcoma herpesvirus and virus-associated cancers.

## Fields

- Kind: Institution
- Last checked: 2026-09-09
- City: Chapel Hill, NC, US
- Type: cancer-center
- NCI designation: comprehensive
- Website: https://unclineberger.org

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/UNC_Lineberger_Comprehensive_Cancer_Center
- UNC Lineberger: https://unclineberger.org
- Clinical trials: https://unclineberger.org/patientcare/clinical-trials/

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Kaposi sarcoma](https://onco.cc/cancers/kaposi-sarcoma/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [CDK4/6 inhibitors](https://onco.cc/technologies/cdk46-inhibitor/)
- institutions: [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- terms: [PAM50 / intrinsic subtypes](https://onco.cc/terms/pam50/)
- people: [Charles M. Perou](https://onco.cc/people/charles-perou/), [Ethan Basch](https://onco.cc/people/ethan-basch/), [Robert L. Ferris](https://onco.cc/people/robert-ferris/)
- bottlenecks: [Patients lack understanding, navigation and agency](https://onco.cc/bottlenecks/b-patient-voice/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)
- key papers: [Molecular portraits of human breast tumours](https://onco.cc/key-papers/paper-perou-molecular-portraits-breast-tumours-nature-2000/), [Purity Independent Subtyping of Tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer](https://onco.cc/key-papers/paper-rashid-purist-pancreatic-subtype-classifier-ccr-2020/), [Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study](https://onco.cc/key-papers/paper-carey-race-breast-cancer-subtypes-cbcs-jama-2006/), [Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma](https://onco.cc/key-papers/paper-moffitt-virtual-microdissection-subtypes-nat-genet-2015/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/), [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/unc-lineberger.json